May 5, 2025 – United States President Donald Trump on Monday signed an executive order to boost domestic production of prescription drugs, including essential ingredients and materials required for their manufacture. The order is aimed at promoting American-made prescription medications by reducing the time it takes to approve pharmaceutical manufacturing plants in the country.
The new order directs the U.S. FDA to
- Streamline reviews, eliminate unnecessary requirements, and collaborate with domestic manufacturers to offer early assistance before their facilities become operational.
- Increase inspections as well as fees for foreign manufacturing plants.
- Strengthen enforcement of API source reporting by overseas drug manufacturers.
- Consider publicly revealing the names of facilities that fail to comply.
Trump’s new order also directs the EPA to facilitate construction of facilities designed to produce prescription drugs, active pharmaceutical ingredients, and other essential raw materials. It mandates a single point of contact for federal permits related to domestic pharmaceutical manufacturing facilities.
Views and Statements
The executive order is part of a broader effort to shift pharmaceutical manufacturing to the United States. It aims to reduce regulatory barriers and streamline the approval process for domestic pharmaceutical manufacturing facilities.
During the signing of the executive order, Marty Makary, FDA commissioner, said that the FDA will begin doing surprise inspections of overseas plants. He stressed that this move is intended to ensure higher safety and quality standards of imported pharmaceutical products.
Trump has repeatedly threatened tariffs on pharmaceutical imports during the last few months. By signing the new executive order, he wants to decrease the nation’s dependence on foreign suppliers for essential drugs.
Trump has emphasized the importance of producing critical medicines and ingredients within the United States. “We do not want to purchase our pharmaceuticals from other nations because if we are in a war, we’re in trouble – So, we need to make our own medications”, Trump said in a statement.
Trump further added, “As we invest in the future, we will permanently bring our medical supply chains back home. We will produce our pharmaceuticals, medical supplies, and treatments right here in the United States.”
Impact and Future Outlook
The executive order is expected to significantly enhance U.S. drug manufacturing capabilities as well as drive demand for domestically produced APIs. This, in turn, will create growth avenues for active pharmaceutical ingredient manufacturers in the nation.
Global pharmaceutical companies may look to relocate parts of their API supply chains to the United States to cope with tariffs and restrictions. This shift will likely have a profound impact on the United States’ share in the global active pharmaceutical ingredients market in the coming years.
Sources:
News Outlet: Reuters
The White House
